Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis

Eric L. Matteson, Frank Buttgereit, Christian Dejaco, Bhaskar Dasgupta

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Diagnosis of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) is based on typical clinical, histologic, and laboratory features. Ultrasonographic imaging in PMR with assessment especially of subdeltoid bursitis can aid in diagnosis and in following response to treatment. In GCA, diagnosis and disease activity are supported with ultrasonographic, MRI, or [18F]fluorodeoxyglucose PET evaluation of large vessels. Glucocorticoids are the primary therapy for PMR and GCA. Methotrexate may be used in patients at high risk for glucocorticoid adverse effects and patients with frequent relapse or needing protracted therapy. Other therapeutic approaches including interleukin 6 antagonists are under evaluation.

Original languageEnglish (US)
Pages (from-to)75-90
Number of pages16
JournalRheumatic Disease Clinics of North America
Issue number1
StatePublished - 2016


  • Giant cell arteritis
  • Glucocorticoids
  • Polymyalgia rheumatica
  • Treatment

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis'. Together they form a unique fingerprint.

Cite this